When to Test for Vitamin B12
Test serum vitamin B12 (either total B12 or active B12) when patients present with suggestive symptoms/signs OR have identifiable risk factors for deficiency. 1
Clinical Indications for Testing
Symptoms and Signs Warranting Testing
Test B12 when patients present with:
Hematological findings:
- Macrocytosis or anemia on blood count
- Iron-refractory anemia during pregnancy/breastfeeding 1
Neurological manifestations:
- Peripheral neuropathy: pins and needles, numbness, paraesthesia
- Myelopathy: balance issues, falls from impaired proprioception, sensory ataxia, impaired gait
- Optic nerve dysfunction: blurred vision, optic atrophy, visual field loss 1
Cognitive/psychiatric symptoms:
- "Brain fog," difficulty concentrating, short-term memory loss
- Unexplained fatigue
- Glossitis 1
Risk Factors Requiring Testing
Dietary risks:
- Vegan diet or diets excluding animal products (religious/cultural)
- No fortified food consumption
- Food allergies (eggs, milk, fish)
- Difficulty buying/preparing food (dementia, frailty, mental health conditions, low income)
- Eating disorders 1
Medical conditions:
- Atrophic gastritis (gastric body)
- Autoimmune diseases: celiac disease, thyroid disease, Sjögren syndrome, type 1 diabetes
- Family history of B12 deficiency or autoimmune conditions 1
Medications:
- Metformin (particularly important given MHRA safety warnings)
- H2 receptor antagonists
- Colchicine
- Phenobarbital, pregabalin, primidone 1
Diagnostic Algorithm
First-Line Testing
Use either total B12 (serum cobalamin) OR active B12 (serum holotranscobalamin) as the initial test. 1
While active B12 is theoretically more accurate (measures biologically active form), the 2024 NICE guideline acknowledges insufficient evidence to mandate its use over total B12 despite the 9-fold cost difference (£18 vs £2). Either test is acceptable when clinical suspicion exists. 1
Important exceptions: Different testing approaches apply for pregnant patients and those with suspected nitrous oxide-related deficiency (consult full guidelines). 1
Interpreting Initial Results
| Total B12 | Active B12 | Interpretation | Action |
|---|---|---|---|
| <180 ng/L (<133 pmol/L) | <25 pmol/L | Confirmed deficiency | Treat immediately |
| 180-350 ng/L (133-258 pmol/L) | 25-70 pmol/L | Indeterminate - possible deficiency | Consider MMA testing |
| >350 ng/L (>258 pmol/L) | >70 pmol/L | Deficiency unlikely | Consider alternative diagnoses |
Second-Line Testing for Indeterminate Results
Consider measuring methylmalonic acid (MMA) when initial B12 results fall in the indeterminate range. 1
MMA provides more reliable functional assessment of B12 status but is unsuitable as first-line testing due to:
- High cost (£11-80 per test)
- Requires specialist equipment
- External laboratory processing with delayed turnaround 1
Cost-effectiveness analysis shows MMA testing before treatment has an incremental cost-effectiveness ratio of £3,946 per quality-adjusted life year when initial results are indeterminate. 1
Critical caveat: MMA and homocysteine can be elevated in other conditions beyond B12 deficiency, limiting their specificity. 2, 3
Common Pitfalls to Avoid
Don't delay treatment for confirmatory testing when clinical suspicion is high with neurological symptoms - neurological damage can become irreversible. 4, 5
Don't rely solely on serum B12 levels - clinical symptoms should receive highest priority in diagnosis. Integrate clinical presentation with laboratory findings. 4, 3
Don't use biomarkers to "titrate" injection frequency during long-term treatment - this practice lacks evidence and should be avoided. 5
Don't assume normal B12 levels exclude deficiency - up to 50% of patients with functional deficiency may have borderline-normal serum levels, particularly when symptoms are present. 4, 5
Don't forget to assess causality - identifying the underlying cause (dietary, malabsorption, medications, autoimmune) guides appropriate long-term management. 6, 4
Treatment Principles
Once deficiency is confirmed:
Severity-based approach:
- Acute/severe manifestations (neurological symptoms): Parenteral B12 (intramuscular) is first-line regardless of cause 4, 5
- Dietary deficiency without severe symptoms: Oral supplementation may be adequate 5
- Malabsorption: Parenteral therapy preferred; oral supplementation likely insufficient 5
Long-term management: After initial loading, many patients require individualized injection regimens (ranging from every 2 months to twice weekly) based on symptom control, not biomarker levels. 5